AIMS: BAP1 and PBRM1 expression loss has been observed in multiple cancers, including intrahepatic cholangiocarcinoma (ICC). We investigated BAP1 and PBRM1 expression in ICC using immunohistochemistry, and analysed its association with clinicopathological and genetic features, including two histological subtypes. METHODS AND RESULTS: Whole-section slides of 108 consecutive primary ICC cases were immunostained against BAP1 and PBRM1. Complete loss of BAP1 and PBRM1 was observed in 21 (19.4%) and 25 (23.1%) cases, respectively, and partial loss was identified in four (3.7%) and nine (8.4%) cases. In all cases, normal bile ducts were strongly and diffusely positive for both BAP1 and PBRM1. ICC with BAP1 loss showed lower serum CA19-9 levels, less perineural invasion, rare mucin production, weaker immunoreactivity against S-100P and stronger immunoreactivity against N-cadherin and NCAM. IDH mutations were identified more frequently in ICCs with BAP1 loss. All ICC with BAP1 loss corresponded to small-duct type ICC. Multivariate Cox regression analysis showed that BAP1 loss was an independent prognostic factor for both overall and recurrence-free survival (P < 0.05). Conversely, PBRM1 loss was found in both small-duct type and large-duct type ICC, and was not associated significantly with any specific characteristics, including prognosis. CONCLUSION: BAP1 and PBRM1 loss is seen frequently in ICC. ICC with BAP1 loss shares features of small-duct type ICC.
AIMS: BAP1 and PBRM1 expression loss has been observed in multiple cancers, including intrahepatic cholangiocarcinoma (ICC). We investigated BAP1 and PBRM1 expression in ICC using immunohistochemistry, and analysed its association with clinicopathological and genetic features, including two histological subtypes. METHODS AND RESULTS: Whole-section slides of 108 consecutive primary ICC cases were immunostained against BAP1 and PBRM1. Complete loss of BAP1 and PBRM1 was observed in 21 (19.4%) and 25 (23.1%) cases, respectively, and partial loss was identified in four (3.7%) and nine (8.4%) cases. In all cases, normal bile ducts were strongly and diffusely positive for both BAP1 and PBRM1. ICC with BAP1 loss showed lower serum CA19-9 levels, less perineural invasion, rare mucin production, weaker immunoreactivity against S-100P and stronger immunoreactivity against N-cadherin and NCAM. IDH mutations were identified more frequently in ICCs with BAP1 loss. All ICC with BAP1 loss corresponded to small-duct type ICC. Multivariate Cox regression analysis showed that BAP1 loss was an independent prognostic factor for both overall and recurrence-free survival (P < 0.05). Conversely, PBRM1 loss was found in both small-duct type and large-duct type ICC, and was not associated significantly with any specific characteristics, including prognosis. CONCLUSION:BAP1 and PBRM1 loss is seen frequently in ICC. ICC with BAP1 loss shares features of small-duct type ICC.
Authors: Ahmet M Aydin; Nirmish Singla; Vandana Panwar; Solomon L Woldu; Yuval Freifeld; Christopher G Wood; Jose A Karam; Alon Z Weizer; Jay D Raman; Mesut Remzi; Nathalie Rioux-Leclercq; Andrea Haitel; Marco Roscigno; Christian Bolenz; Karim Bensalah; Mary E Westerman; Arthur I Sagalowsky; Shahrokh F Shariat; Yair Lotan; Aditya Bagrodia; Payal Kapur; Vitaly Margulis; Laura-Maria Krabbe Journal: World J Urol Date: 2019-02-13 Impact factor: 4.226
Authors: Claudio Luchini; Scott A Robertson; Seung-Mo Hong; Matthäus Felsenstein; Robert A Anders; Antonio Pea; Alessia Nottegar; Nicola Veronese; Jin He; Matthew J Weiss; Paola Capelli; Aldo Scarpa; Pedram Argani; Payal Kapur; Laura D Wood Journal: Histopathology Date: 2017-06-22 Impact factor: 5.087
Authors: Helen Winter; Pamela J Kaisaki; Joe Harvey; Edoardo Giacopuzzi; Matteo P Ferla; Melissa M Pentony; Samantha J L Knight; Ricky A Sharma; Jenny C Taylor; James S O McCullagh Journal: Cancers (Basel) Date: 2019-11-28 Impact factor: 6.639